Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Lymphoma: From Molecular Biology to Targeted Therapy
share announcement

Lymphoma: From Molecular Biology to Targeted Therapy

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 5072

Special Issue Editors

Dr. Thomas E. Witzig

E-Mail Website
Guest Editor
Mayo Clinicdisabled, Rochester, USA
Interests: Lymphoma, DNA damage repair, metabolomics, nuclear cytoplasmic molecular export
Dr. Jithma P. Abeykoon

E-Mail Website
Guest Editor
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Interests: lymphoma (clinical and translational science); experimental therapeutics; DNA damage repair; nuclear cytoplasmic transport systems; biological; prognostic and therapeutic aspect of Waldenstrom macroglobulinemia; indolent and aggressive non-Hodgkin lymphoma
Dr. Saurabh Zanwar

E-Mail Website
Guest Editor
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Interests: Waldenstrom Macroglobulinemia, Indolent Lymphomas, Multiple Myeloma, experimental therapeutics, biomarkers
Dr. Xavier Andrade-Gonzalez

E-Mail Website
Guest Editor
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Interests: Lymphoma, geriatric oncology, biomarkers, outcomes-based research

Special Issue Information

Dear Colleagues,

We are pleased invite you to contribute your research to this Special Issue of Biomolecules. In this Issue, we aim to focus on exploring the current knowledge of the molecular pathways and mechanisms involved in the oncogenesis of Hodgkin and non-Hodgkin lymphoma, and to examine their role as potential therapeutic targets. Therefore, special emphasis will be given to the following important topics: 1) mechanisms associated with DNA synthesis, 2) prognostic and therapeutic implications of metabolomics/micronutrients, 3) nuclear-cytoplasmic molecular export and 4) any research focused on molecular biology and targeted therapy in Hodgkin and non-Hodgkin lymphoma.

We look forward to your original research pertaining to the abovementioned key topics in Hodgkin and non-Hodgkin lymphoma. Research conducted in preclinical, translational, retrospective, or prospective settings is welcome.

Dr. Thomas E. Witzig
Dr. Jithma Abeykoon
Dr. Saurabh Zanwar
Dr. Xavier Andrade-Gonzalez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • New insights into the pathobiology of lymphoma;
  • Genomic, epigenomic, transcriptomic and proteomic alterations in lymphoma;
  • New mechanisms such as nucleocytoplasmic molecular export in lymphoma;
  • Significance of metabolomics/micronutrients in lymphoma;
  • Therapeutic significance of new targeted treatments in lymphoma.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1199 KiB  
Article
Alternative c-MYC mRNA Transcripts as an Additional Tool for c-Myc2 and c-MycS Production in BL60 Tumors
by Dina Ibrahim, Léa Prévaud, Nathalie Faumont, Danielle Troutaud, Jean Feuillard, Mona Diab-Assaf and Ahmad Oulmouden
Biomolecules 2022, 12(6), 836; https://doi.org/10.3390/biom12060836 - 16 Jun 2022
Cited by 1 | Viewed by 2484
Abstract
While studying c-Myc protein expression in several Burkitt lymphoma cell lines and in lymph nodes from a mouse model bearing a translocated c-MYC gene from the human BL line IARC-BL60, we surprisingly discovered a complex electrophoretic profile. Indeed, the BL60 cell line carrying [...] Read more.
While studying c-Myc protein expression in several Burkitt lymphoma cell lines and in lymph nodes from a mouse model bearing a translocated c-MYC gene from the human BL line IARC-BL60, we surprisingly discovered a complex electrophoretic profile. Indeed, the BL60 cell line carrying the t(8;22) c-MYC translocation exhibits a simple pattern, with a single c-Myc2 isoform. Analysis of the c-MYC transcripts expressed by tumor lymph nodes in the mouse λc-MYC (Avy/a) showed for the first time five transcripts that are associated with t(8;22) c-MYC translocation. The five transcripts were correlated with the production of c-Myc2 and c-MycS, and loss of c-Myc1. The contribution of these transcripts to the oncogenic activation of the t(8;22) c-MYC is discussed. Full article
(This article belongs to the Special Issue Lymphoma: From Molecular Biology to Targeted Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 321 KiB  
Review
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
by Kyla L. Trkulja, Farheen Manji, John Kuruvilla and Rob C. Laister
Biomolecules 2023, 13(1), 111; https://doi.org/10.3390/biom13010111 - 05 Jan 2023
Cited by 3 | Viewed by 1808
Abstract
Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins [...] Read more.
Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins and RNA that are involved in cancer progression and treatment resistance. Here, we discuss the proteins and RNA transcripts that have been identified as XPO1 cargo in NHL lymphoma including tumour suppressors, immune modulators, and transcription factors, and their implications for oncogenesis. We then highlight the research to date on XPO1 inhibitors such as selinexor and other selective inhibitors of nuclear export (SINEs), which are used to treat some cases of non-Hodgkin lymphoma. In vitro, in vivo, and clinical studies investigating the anti-cancer effects of SINEs from bench to bedside, both as a single agent and in combination, are also reported. Finally, we discuss the limitations of the current research landscape and future directions to better understand and improve the clinical utility of SINE compounds in NHL. Full article
(This article belongs to the Special Issue Lymphoma: From Molecular Biology to Targeted Therapy)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop